ABT Abbott Stock Outlook 2026: FreeStyle Libre's CGM Moat Is Widening While Dexcom Struggles

One Data Point That Explains Why Abbott’s Selloff Is an Opportunity

Abbott Laboratories lost roughly 37% from its 52-week high of $139.06 to its current price of $87.01. The proximate cause is well understood: COVID-19 diagnostic test revenues that had inflated earnings are gone, and the market de-rated the stock accordingly.

But buried inside that compression is a business that barely everyone talks about in the earnings coverage: FreeStyle Libre.

The Libre platform now serves tens of millions of people globally with continuous glucose monitoring (CGM). The addressable market is enormous — the International Diabetes Federation estimates 537 million adults living with diabetes worldwide, with CGM penetration in the low single digits. Every year, more of those patients graduate to real-time monitoring. And in most markets outside the United States, Abbott’s Libre is the default choice.

Abbott’s CGM moat is widening as Dexcom struggles with G7 launch friction in international markets and pricing dynamics that favor Abbott in the faster-growing Type 2 and emerging-market segments. Meanwhile, the stock is at a 15x forward earnings multiple — below its own 10-year average — while the core growth driver is structurally accelerating.

That is the setup for 2026.

---

Financial Snapshot

Metric	Value (May 2026)
Stock Price	$87.01
Market Cap	$151.6B
P/E (GAAP)	24.37x
Forward P/E	15.53x
Dividend Yield	2.90%
Annual Dividend/Share	$2.52
52-Week Range	$86.15 – $139.06
Analyst Consensus Target	$130.90
FY2025 Revenue	$44.33B
FY2025 Diluted EPS	$3.72
TTM Revenue (Q1 2026)	$45.13B

The current price of $87.01 is essentially at the 52-week low ($86.15), indicating the stock has found a floor near these levels. The 20-analyst Strong Buy consensus with $130.90 target represents the largest upside gap on the healthcare large-cap spectrum.

---

Four Segments: What Drives Growth and What Is Just Stable Cash

Medical Devices — The Growth Engine

This segment is where Abbott wins long-term. FreeStyle Libre is the flagship, but the segment also includes:

• Electrophysiology: Cardiac ablation catheters and mapping systems. Abbott holds a competitive position in the atrial fibrillation (AFib) treatment market, which is growing as catheter ablation becomes the preferred first-line treatment over drugs in certain patient profiles.
• Structural Heart: Transcatheter aortic valve replacement (TAVR) is dominated by Edwards Lifesciences and Medtronic, but Abbott competes in adjacent spaces (mitral valve, left atrial appendage closure).
• Neuromodulation: Spinal cord stimulation and deep brain stimulation devices.

Diagnostics — Normalized, No Longer a Headwind

The COVID-19 testing boom distorted this segment beyond recognition. Rapid antigen tests generated billions in extraordinary revenue in 2021–2022. By 2025, the segment has fully normalized. Core laboratory testing (hematology, immunoassay) is a durable, low-growth business; the COVID effect is now a year-over-year noise factor of zero.

Established Pharmaceuticals — Emerging Market Annuity

Abbott’s established pharma business sells branded generic medications in emerging markets — primarily India, China, Russia, and Latin America. It’s not a growth business in the conventional sense, but it generates consistent cash flows with minimal R&D investment.

Nutrition — Post-Recall Recovery

Similac infant formula faced a catastrophic recall event in 2022 (Sturgis plant contamination), contributing to the US baby formula shortage. The plant has been operating normally since late 2022. The adult nutrition franchise (Ensure, Glucerna) benefits from aging demographics and is a stable mid-single-digit growth business.

Segment	Growth Profile	COVID Impact	Risk Level
Medical Devices	High (CGM-driven)	None	Competitive
Diagnostics	Flat-to-low	Very high (normalized)	Low
Established Pharma	Stable	None	Regulatory/FX
Nutrition	Stable-to-moderate	None	Execution

---

FreeStyle Libre: Why the Moat Is Getting Wider, Not Narrower

The CGM market is essentially a two-horse race between Abbott and Dexcom. Here is why Abbott’s position is arguably stronger today than two years ago:

Global First-Mover Advantage: Abbott launched Libre in Europe before the US and built a dominant user base. European reimbursement frameworks are often more favorable to Libre, and switching costs for established CGM users are high.

Price Architecture: Libre is priced below Dexcom in most markets, making it the de facto choice for newly diagnosed Type 2 diabetics and for healthcare systems with formulary budget constraints. As CGM expands from Type 1 into the vastly larger Type 2 population, Abbott’s price positioning is strategically correct.

Libre 3 Closes Feature Gap: The previous criticism that Libre lacked real-time continuous data transmission (it used flash scanning) was addressed with Libre 3, which provides continuous, real-time readings with an extremely small sensor form factor.

Dexcom’s G7 Launch Friction: Dexcom experienced supply chain and training challenges when rolling out G7 internationally. Abbott has used this window to extend its installed base.

Our view: Abbott’s CGM moat is not just wide — it is widening specifically in the segments (Type 2 diabetes, international, price-sensitive markets) that represent the majority of future market growth.

---

52-Year Dividend Streak: The Long Game

Abbott has raised its dividend for over 52 consecutive years. This streak includes recessions, financial crises, inflation spikes, and the company’s own product crises (the Similac recall). The consistency is remarkable.

Year	Annual Dividend	Approximate Yield
2016	$1.04	~2.2%
2018	$1.12	~1.7%
2020	$1.44	~1.6%
2022	$1.88	~1.7%
2024	$2.36	~1.9%
2026	$2.52	2.90%

The 2.90% yield at current prices is at the high end of Abbott’s historical range, reflecting the price compression from COVID normalization. Dividend growth has averaged approximately 10% annually over the past decade.

For IRA and 401k investors, Abbott’s qualified dividend status means no tax drag within tax-advantaged accounts. A $100K position returning 2.90% in dividends generates $2,900 annually — tax-free in a Roth IRA context.

---

12-Month Price Target Scenarios

Scenario	Assumptions	Target Price	vs. Current
Bull	FreeStyle Libre guidance raised, electrophysiology acceleration, multiple expansion to 19x	$145	+67%
Base	Consensus execution, CGM 15% YoY growth, dividend raised to $2.76	$125	+44%
Bear	Dexcom recovers aggressively, US recession delays elective procedures, formula recall repeat	$75	-14%

The consensus target of $130.90 aligns with the base scenario. The bull case at $145 is achievable if CGM revenues surprise to the upside — which they have consistently done for the past three years.

---

Risks

CGM Competition Intensification: Beyond Dexcom, Senseonics offers an implantable 180-day CGM (Eversense), and Medtronic continues to invest in integrated pump-CGM systems. Long-term, CGM commoditization is a real risk — the question is over what time horizon.

Structural Heart Competition: Abbott’s position in TAVR adjacencies is not dominant. Edwards Lifesciences and Medtronic have stronger brand positions in the core TAVR market.

Inflation and Supply Chain: Medical device manufacturing is capital-intensive and subject to component cost inflation, particularly for semiconductor-dependent continuous monitoring systems.

Drug Pricing in Emerging Markets: The established pharmaceuticals segment operates in markets where local governments frequently negotiate or regulate medication prices. This limits upside but also limits downside given the branded-generic positioning.

Formula Recall Risk: The 2022 Similac event was a reputational and operational shock. While no recurrence has occurred, the nutrition segment carries execution risk that is not present in the medical devices business.

---

Abbott vs. the Peer Healthcare Landscape

Abbott’s 2.90% yield is lower than AbbVie (3.41%), J&J, or Pfizer, but its medical device mix provides a different risk profile — less exposure to drug pricing risk, more exposure to procedure volume and device adoption cycles.

The 52-year dividend streak is unmatched by AbbVie (which only has 13 years post-spinoff), and Abbott’s four-segment diversification means no single drug or product accounts for a disqualifying percentage of revenue.

For investors who want healthcare exposure with lower drug-pricing risk and a device/CGM growth story, Abbott is the logical complement to the pharma-heavy positions.

---

Our Position

Abbott is the most undervalued large-cap dividend grower in the healthcare sector at current prices. The COVID normalization that caused the selloff is complete — 2025 financials represent a clean baseline of $44.3B revenue and $3.72 EPS. From that foundation, FreeStyle Libre-driven CGM growth provides a structural tailwind that is independent of drug pricing legislation, biosimilar threats, or patent cliffs.

At $87 with a 15.5x forward P/E, a 2.90% dividend yield growing at ~10% annually, and 20 analysts at Strong Buy targeting $130.90, the risk/reward asymmetry favors the long side. The 52-week low at $86.15 acts as a near-term floor.

Accumulation in the $86–95 range with a 12-18 month horizon is the way to play this.

---

Related Healthcare Stock Analysis

• JNJ Johnson & Johnson Stock Outlook 2026
• LLY Eli Lilly Stock Outlook 2026
• PFE Pfizer Dividend & Stock Analysis
• MRK Merck Stock Outlook
• BMY Bristol-Myers Squibb Outlook